Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (17)

2024

  1. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  3. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

    Clinical and Translational Oncology, Vol. 25, Núm. 1, pp. 283-291

  2. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  3. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 1-7

  4. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

    Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476

2022

  1. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges

    Clinical Cancer Research, Vol. 28, Núm. 12, pp. 2506-2516

  2. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

2021

  1. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  2. Impact of the COVID-19 pandemic on the care of cancer patients in Spain

    ESMO open, Vol. 6, Núm. 3, pp. 100157

  3. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  4. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

    BMC Psychology, Vol. 8, Núm. 1

2019

  1. Lung cancer in Spanish women: The WORLD07 project

    European Journal of Cancer Care, Vol. 28, Núm. 1

2017

  1. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

2014

  1. Lung cancer in women: An overview with special focus on Spanish women

    Clinical and Translational Oncology, Vol. 16, Núm. 6, pp. 517-528